Infectious Disease · Pneumococcal Vaccination
The successful phase 3 trial of V116 demonstrates its potential to become a preferred pneumococcal vaccination option for high-risk children, which could significantly alter vaccination practices. This shift may lead to increased market share for V116 at the expense of existing vaccines like PPSV23, necessitating close monitoring of regulatory developments and guideline updates.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 6/25/2026, 6:03:59 AM
Assessment confidence: 86% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.
The successful phase 3 trial of V116 demonstrates its potential to become a preferred pneumococcal vaccination option for high-risk children, which could significantly alter vaccination practices. This shift may lead to increased market share for V116 at the expense of existing vaccines like PPSV23, necessitating close monitoring of regulatory developments and guideline updates. Regulatory context from FDA (FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)) supports the near-term read. Assessment grounded in 9 ranked evidence items (8 high-relevance).
Strategic focus may shift towards expanding vaccination programs for high-risk children, with potential for increased uptake of V116 in pediatric guidelines. The strongest clinical anchor is A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease (ClinicalTrials.gov), sub-indication match (ild). In ild, 4 regulatory and 1 competitive items passed relevance filtering for PPSV23.
The most relevant competitive pressure comes from U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease (Merck) — sub-indication match (ild); sponsor/company relevance (merck).
Regulatory risk is concentrated around FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL) (FDA). Sub-indication match (ild); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The trial results will likely influence regulatory approval processes and may expedite the inclusion of V116 in pediatric vaccination recommendations, affecting compliance and market access.
FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)
FDAhigh relevance
Sub-indication match (ild); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — CHILDREN'S ADVIL (SUPPL)
FDAhigh relevance
Sub-indication match (ild); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — CHILDREN'S CLARITIN (SUPPL)
FDAhigh relevance
Sub-indication match (ild); Regulatory pathway relevance (nda)
FDA document
View sourceLower dose needle-free allergy treatment approved for younger children
MHRAhigh relevance
Sub-indication match (ild)
FDA document
View sourceHepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceOffice of New Drugs Custom Medical Queries (OCMQs) for Safety Signal Detection in Clinical Trial Data - 06/23/2026
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceLessons Learned from our Roundtable with Rare Disease Advocates
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceA Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
ClinicalTrials.govhigh relevance
Sub-indication match (ild)
FDA document
View sourceHost and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali
ClinicalTrials.govmedium relevance
Sub-indication match (ild)
FDA document
View sourceA Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceA Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceA Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceA Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceU.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
Merckhigh relevance
Sub-indication match (ild); Sponsor/company relevance (Merck)
FDA document
View sourceA phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedhigh relevance
Sub-indication match (ild)
FDA document
View sourceImmunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedhigh relevance
Sub-indication match (ild)
FDA document
View sourceSafety and immunogenicity of a booster dose of COVAC-2, Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in previously vaccinated healthy adults; a randomized controlled multicentre tria
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceSafety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe successful phase 3 trial of V116 demonstrates its potential to become a preferred pneumococcal vaccination option for high-risk children, which could significantly alter vaccination practices. This shift may lead to increased market share for V116 at the expense of existing vaccines like PPSV23, necessitating close monitoring of regulatory developments and guideline updates.
If V116 is adopted widely in vaccination guidelines, it could capture a substantial share of the pediatric vaccination market, impacting revenue streams for competitors like PPSV23.
The trial results will likely influence regulatory approval processes and may expedite the inclusion of V116 in pediatric vaccination recommendations, affecting compliance and market access.
Monitor regulatory approval timelines and potential adoption in vaccination guidelines for high-risk pediatric populations.
Track for follow-up milestones; no immediate action required.